ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Genome-scale Metabolic Modeling Guided Escherichia coli Engineering for De Novo Biosynthesis of Chrysanthemic Acid.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genome-scale Metabolic Modeling Guided Escherichia coli Engineering for De Novo Biosynthesis of Chrysanthemic Acid.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Multiobjective Design of Growth Media with Genome-Scale Metabolic Models and Bayesian Optimization.Computational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chrysanthemic acid is an unconventional monoterpene moiety of the natural pesticide pyrethrins with notable anti-insect activity, making its industrial biosynthesis a promising avenue for sustainable agriculture. Here, an E. coli cell factory is designed and build for highly efficient chrysanthemic acid production guided by Genome-scale metabolic models (GEM). The biosynthetic pathway is reconstructed and simulated the metabolic changes caused by exogenous modules are simulated. A key metabolic branch point catalyzed by ispA is identified by this model, and inhibiting its expression using synthetic small RNA redirected the metabolic flux, resulting in the titers of precursor chrysanthemol and chrysanthemic acid increasing by 162% and 59%, respectively. The effect of the expression level of downstream dehydrogenases on chrysanthemic acid titer is also predicated using GEM, and the further optimization of copy number for dehydrogenase genes led to a notably 570% increase in chrysanthemic acid titer experimentally. By integrating the debranching strategy with copy number optimization, a record chrysanthemic acid titer 141.78 mg L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.